Key facts
- This page summarizes Aaron Kantoff's Form 4 filing for Centessa Pharmaceuticals plc (CNTA).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 18 Nov 2021, 19:30.
Aaron Kantoff - 18 Nov 2021 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)
- Reporting relationship
- Director
- Issuer ticker
- CNTA
- Reported as of
- 18 Nov 2021
- Net transaction value
- +$119,850
- SEC form
- 4
- Accepted by SEC
- 18 Nov 2021, 19:30:09 UTC
- Prior SEC filing
- 27 May 2021
- Next SEC filing
- 23 Oct 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Marella Thorell, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Aaron Kantoff filed Form 4 for Centessa Pharmaceuticals plc (CNTA) on 18 Nov 2021.
Change
- Previous filing in this sequence was filed on 27 May 2021.
- Current net transaction value: +$119,850.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CNTA
transaction
Ordinary Shares
Purchase
- Transaction value
- $119,850
- Shares
- +10,000
- Change %
- +20%
- Price
- $11.98
- Shares after
- 60,000
- Date
- 18 Nov 2021
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.